Nortriptyline Use in Adolescents: Safety Concerns and Alternatives

Introduction to Safety Concerns

Tricyclic antidepressants like nortriptyline have high lethal potential in overdose, making them particularly dangerous in suicidal youth who may have access to their own medications, according to the American Academy of Child and Adolescent Psychiatry 1, 2

The American Academy of Child and Adolescent Psychiatry recommends SSRIs as the preferred first-line pharmacological treatment for adolescent depression and anxiety, not tricyclic antidepressants, due to their superior efficacy and lower toxicity in overdose 1
Fluoxetine has the most robust evidence for safety and efficacy in adolescents aged 12 years and older, and is FDA-approved for depression in children aged 8 years and older, as stated by the American Academy of Pediatrics 3
Escitalopram is FDA-approved for adolescents aged 12-17 years with depression, as recommended by the American Academy of Child and Adolescent Psychiatry 3
Tricyclic antidepressants have been shown to be less effective than SSRIs in treating adolescent depression in placebo-controlled studies, while SSRIs demonstrate clear efficacy, according to the American Academy of Child and Adolescent Psychiatry 1

The American Academy of Child and Adolescent Psychiatry explicitly states that tricyclics should not be prescribed to suicidal children and adolescents because of their greater lethal potential 2
Even for ADHD comorbid with depression, stimulants are preferred over tricyclics despite tricyclics having some efficacy for ADHD, specifically because of the overdose risk, as recommended by the American Academy of Child and Adolescent Psychiatry 2

If nortriptyline is prescribed against guideline recommendations, assessment should occur within 1 week of initiation and regularly thereafter, evaluating depressive symptoms, suicide risk, adverse effects, adherence, and environmental stressors, as stated by the American Academy of Pediatrics 4, 5

The American Academy of Pediatrics-recommended fluoxetine is approved for children aged 8 years and older for depression, making it the only option with approval in the younger pediatric population 6
The FDA-approved escitalopram is approved only for adolescents 12 years and older 6

In adolescent-specific analyses, escitalopram demonstrated significant improvement in depression symptoms compared to placebo, particularly in the 12-17 year age group, with moderate-strength evidence 7, 8
The evidence specifically shows that escitalopram was superior to placebo in adolescents but NOT in children, with moderate-strength evidence 7, 8

The American Academy of Child and Adolescent Psychiatry recommends reducing imipramine from 200 mg to 150 mg daily (25% reduction) during the initial taper, while simultaneously starting escitalopram 10 mg daily 9
The American Academy of Child and Adolescent Psychiatry suggests reducing imipramine from 150 mg to 100 mg daily, and then from 100 mg to 50 mg daily, while continuing escitalopram 10 mg daily 9
If severe withdrawal symptoms occur, the American Academy of Child and Adolescent Psychiatry recommends slowing the taper or temporarily increasing the imipramine dose before resuming a slower taper 9
The American Academy of Child and Adolescent Psychiatry advises reducing imipramine from 50 mg to 25 mg daily for 3-4 days, then discontinuing, while continuing escitalopram 10 mg daily 9